热门资讯> 正文

Larimar Therapeutics的GAAP每股收益为-0.73美元，差0.22美元

2026-03-19 19:21

Larimar Therapeutics, Inc.(LRMR) 0

Larimar Therapeutics press release (LRMR): Q4 GAAP EPS of -$0.73 misses by $0.22.
$244.5 million in pro forma cash, cash equivalents and marketable securities as of December 31, 2025, with projected cash runway into the second quarter of 2027

More on Larimar Therapeutics

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Larimar Therapeutics stock dips after pricing $100M share offering
Larimar Therapeutics launches proposed $75 million public offering

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。